Home・Lista de Ações・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Fechado

SetorSaúde

38.61 10.31

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

34.67

Máximo

35.69

Indicadores-chave
By Trading Economics
Rendimento	10M 32M
Vendas	-28M 215M
P/E Médio do Setor	14.233 64.641
EPS	0.79
Margem de lucro	15.084
Funcionários	293
EBITDA	-2.8M 49M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+10.25% upside

Dividendos
By Acuity
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	199M 2.1B
Abertura anterior	28.3
Fecho anterior	38.61

Sentimento de Notícias

By Acuity

100%

320 / 340 Ranking em Healthcare

Harmony Biosciences Holdings Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de ago. de 2026, 23:11 UTC

Harmony Biosciences shares are higher in after-hours trading, supported by positive sentiment from the Institute for Supply Management's manufacturing PMI report.

1 de ago. de 2026, 00:01 UTC

Shares of Harmony Biosciences Holdings Inc are higher in after-market trading, reflecting notable strength since Friday's close without any specific news driving the move.

31 de jul. de 2026, 23:21 UTC

Harmony Biosciences Holdings Inc. is trading higher during after-market hours, reflecting steady price increases since Friday's close, despite no specific news identified.

28 de jul. de 2026, 18:26 UTC

News

Shares of Harmony Biosciences are lower despite a 30% revenue increase for WAKIX, as market sentiment reflects concerns over potential cash flow erosion.

27 de jul. de 2026, 19:41 UTC

Shares of Harmony Biosciences Holdings Inc. are higher today, breaking from a recent upward trend despite the absence of specific company news.

24 de jul. de 2026, 17:06 UTC

Shares of Harmony Biosciences Holdings Inc. are lower today, continuing a decline since Thursday's close, despite earlier reaching a session high.

22 de jul. de 2026, 20:01 UTC

News

Harmony Biosciences Holdings Inc is trading lower despite preliminary Q2 2026 results showing record net product revenue of approximately $261 million, a 30% year-over-year increase.

21 de jul. de 2026, 21:01 UTC

Harmony Biosciences Holdings Inc. shares are lower in after-market trading, diverging from a broader market rebound despite no specific news driving the decline.

Comparação entre Pares

Variação de preço

Harmony Biosciences Holdings Inc Previsão

Preço-alvo

By TipRanks

10.25% parte superior

Previsão para 12 meses

Média 39.25 USD 10.25%

Máximo 55 USD

Mínimo 28 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Harmony Biosciences Holdings Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

8 ratings

Comprar

Manter

Vender

Com base em 8 analistas que deram avaliações de ações para Harmony Biosciences Holdings Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

320 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.